Primary mediastinal B-cell lymphoma starts in ... lymphoma affects the brain and spinal cord. Diffuse large B-cell lymphoma not otherwise specified (DLBCL-NOS) are a group of cancers that don ...

Researchers recently concluded that the care received by patients treated by the Veterans Health Administration for diffuse large B-cell lymphoma met the standard of care across races and ...

Three subtypes have been identified by gene-expression studies; germinal center (GC) DLBCL, non-GC DLBCL, and mediastinal large B-cell lymphoma. GC and non-GC DLBCL differ with respect to the cell ...

The guidance covers patients with diffuse large B-cell lymphoma, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and grade 3B follicular lymphoma who would be suitable ...

Long-term data gathered from the TRANSCEND NHL trial have shown that this treatment approach can significantly improve ...

Yescarta (axicabtagene ciloleucel) has been approved as a treatment for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma ...

Diffuse large B-cell lymphoma (DLBCL) is the most common and fast-growing type of non-Hodgkin lymphoma, a cancer that affects ...

Liso-Cel is a type of CAR T-cell therapy — a revolutionary approach that uses a patient's own immune cells to fight cancer.

It is a possible treatment for large B-cell lymphoma (diffuse large B‑cell, high-grade B‑cell, primary mediastinal large B-cell and follicular grade 3B) in adults when: the cancer has: stopped ...

offers hope to people whose diffuse large B-cell lymphoma (DLBCL) has proved hard to treat. First approved by the FDA in 2017, CAR T-cell therapy has the potential to cure your cancer. Here ...

This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody clustering, independent of ...